Last reviewed · How we verify
Lenalidomide (Control)
Lenalidomide is an immunomodulatory agent that enhances T-cell proliferation and NK cell activation while promoting anti-angiogenic and direct anti-tumor effects.
Lenalidomide is an immunomodulatory agent that enhances T-cell proliferation and NK cell activation while promoting anti-angiogenic and direct anti-tumor effects. Used for Multiple myeloma, Myelodysplastic syndromes with deletion 5q, Mantle cell lymphoma.
At a glance
| Generic name | Lenalidomide (Control) |
|---|---|
| Also known as | Revlimid |
| Sponsor | University of Chicago |
| Drug class | Immunomodulatory agent (IMiD) |
| Target | Cereblon (CRBN) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Lenalidomide binds to cereblon (CRBN), a component of an E3 ubiquitin ligase complex, leading to selective degradation of Ikaros and Aiolos proteins. This results in enhanced IL-2 and TNF-α production by T cells, increased NK cell activity, and inhibition of angiogenesis. It also has direct cytotoxic effects on certain tumor cells and modulates the bone marrow microenvironment.
Approved indications
- Multiple myeloma
- Myelodysplastic syndromes with deletion 5q
- Mantle cell lymphoma
- Follicular lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Fatigue
- Constipation
- Diarrhea
- Neuropathy (peripheral)
- Thromboembolism
- Teratogenicity
Key clinical trials
- Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma (PHASE3)
- A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant (PHASE3)
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (PHASE1)
- Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL (PHASE3)
- A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma (PHASE3)
- A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (PHASE1)
- Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma (PHASE3)
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |